What is Leerink Partnrs’ Forecast for Nuvalent Q1 Earnings?

Nuvalent, Inc. (NASDAQ:NUVL) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Nuvalent in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($1.14) per share for the quarter. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent’s FY2025 earnings at ($4.60) EPS, FY2026 earnings at ($5.24) EPS and FY2027 earnings at ($4.11) EPS.

Nuvalent (NASDAQ:NUVL) last issued its earnings results on Tuesday, November 12th. The company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.35). During the same quarter in the prior year, the business posted ($0.59) earnings per share.

Other equities analysts also recently issued reports about the company. BMO Capital Markets lifted their target price on Nuvalent from $132.00 to $134.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Wedbush reiterated an “outperform” rating and set a $115.00 price objective on shares of Nuvalent in a research report on Monday, January 13th. UBS Group initiated coverage on Nuvalent in a research report on Thursday, October 24th. They set a “neutral” rating and a $100.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Nuvalent in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $112.36.

Nuvalent Stock Down 2.7 %

Shares of NUVL stock opened at $83.34 on Monday. The business has a 50 day moving average of $83.49 and a two-hundred day moving average of $88.02. Nuvalent has a 52 week low of $61.79 and a 52 week high of $113.51. The company has a market cap of $5.92 billion, a P/E ratio of -24.02 and a beta of 1.38.

Insiders Place Their Bets

In other Nuvalent news, Director Matthew Shair sold 2,000 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $82.79, for a total value of $165,580.00. Following the transaction, the director now owns 218,522 shares of the company’s stock, valued at approximately $18,091,436.38. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Henry E. Pelish sold 2,483 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $79.68, for a total value of $197,845.44. Following the completion of the transaction, the insider now directly owns 59,981 shares in the company, valued at $4,779,286.08. This represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 83,800 shares of company stock worth $6,812,164 over the last ninety days. Company insiders own 12.52% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NUVL. US Bancorp DE acquired a new stake in Nuvalent during the 4th quarter valued at $90,000. KBC Group NV raised its stake in Nuvalent by 61.1% during the 4th quarter. KBC Group NV now owns 1,587 shares of the company’s stock valued at $124,000 after purchasing an additional 602 shares during the period. Portland Investment Counsel Inc. acquired a new stake in Nuvalent during the 3rd quarter valued at $205,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Nuvalent by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,147 shares of the company’s stock valued at $213,000 after purchasing an additional 382 shares during the period. Finally, Creative Planning acquired a new stake in Nuvalent during the 3rd quarter valued at $232,000. Institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.